Developing a framework to assess the cost-effectiveness of COMPARE - a global platform for the exchange of sequence-based pathogen data

被引:5
作者
Alleweldt, F. [1 ]
Kara, S. [1 ]
Osinski, A. [1 ]
van Baal, P. [2 ]
Kellerborg, K. [2 ]
Aarestrup, F. M. [3 ]
Koopmans, M. [4 ]
机构
[1] Civ Consulting, Potsdamer Str 150, D-10783 Berlin, Germany
[2] Erasmus Univ, Inst Hlth Policy & Management, Boyle Bldg,Campus Woudestein, NL-3062 PA Rotterdam, Netherlands
[3] Tech Univ Denmark, Natl Food Inst, Bldg 221,Room 210, DK-2800 Lyngby, Denmark
[4] Erasmus MC, Dept Virosci, POB 2040,Ee1726, NL-3000 CA Rotterdam, Netherlands
来源
REVUE SCIENTIFIQUE ET TECHNIQUE-OFFICE INTERNATIONAL DES EPIZOOTIES | 2017年 / 36卷 / 01期
基金
欧盟地平线“2020”;
关键词
COMPARE; Cost benefit; Cost-effectiveness; Detection; Genomic information; Next-generation sequencing; Pathogen; Surveillance; ECONOMIC-EVALUATION; DECISION-MAKING; ANIMAL HEALTH; SURVEILLANCE; INTERVENTIONS; ISSUES;
D O I
10.20506/rst.36.1.2631
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Analysing the genomic data of pathogens with the help of next-generation sequencing (NGS) is an increasingly important part of disease outbreak investigations and helps guide responses. While this technology has already been successfully employed to elucidate and control disease outbreaks, wider implementation of NGS also depends on its cost-effectiveness. COMPARE short for 'Collaborative Management Platform for detection and Analyses of (Re-) emerging and foodborne outbreaks' is a major project, funded by the European Union, to develop a global platform for sharing and analysing NGS data and thereby improve the rapid identification, containment and mitigation of emerging infectious diseases and foodborne outbreaks. This article introduces the project and presents the results of a review of the literature, composed of previous relevant cost benefit and cost-effectiveness analyses. The authors also outline the implications for a methodological framework to assess the cost-effectiveness of COMPARE and similar systems.
引用
收藏
页码:311 / 322
页数:12
相关论文
共 35 条
[1]  
Anker M., 2005, EV COSTS BEN NAT SUR
[2]  
[Anonymous], STAT DECISION THEORY
[3]   Issues surrounding the health economic evaluation of genomic technologies [J].
Buchanan, James ;
Wordsworth, Sarah ;
Schuh, Anna .
PHARMACOGENOMICS, 2013, 14 (15) :1833-1847
[4]  
Cellini R.S., 2015, Handbook of practical program evaluation, P636, DOI [10.1002/9781119171386, DOI 10.1002/9781119171386]
[5]   Assessing the Costs and Cost-Effectiveness of Genomic Sequencing [J].
Christensen, Kurt D. ;
Dukhovny, Dmitry ;
Siebert, Uwe ;
Green, Robert C. .
JOURNAL OF PERSONALIZED MEDICINE, 2015, 5 (04) :470-486
[6]  
Civic Consulting, 2016, STUD COST BEN AN REF, DOI [10.2818/788468, DOI 10.2818/788468.]
[7]   The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies [J].
Claxton, K .
JOURNAL OF HEALTH ECONOMICS, 1999, 18 (03) :341-364
[8]  
Drummond MF., 2005, Methods for the Evaluation of Health Care Programmes, V3rd
[9]  
Edejer T. Tan-Torres, 2003, MAKING CHOICES HLTH
[10]   Costs and benefits of a subtype-specific surveillance system for identifying Escherichia coli of O157:H7 outbreaks [J].
Elbasha, EH ;
Fitzsimmons, TD ;
Meltzer, MI .
EMERGING INFECTIOUS DISEASES, 2000, 6 (03) :293-297